He served as Professor of Medicine and Chair of the Department of Clinical Immunology and Rheumatology at the Amsterdam University Medical Center (AMC). He has published extensively in peer-reviewed journals (>600 publications, H-index 157), received numerous awards, has been elected Fellow of the Academy of Medical Sciences, was recognized as 2021 PharmaVOICE100 honoree (100 most inspiring people in life sciences), and included in 'The Medicine Maker Power List’ (2023, 2024, 2026; 30 influential and inspirational leaders across small molecule, biopharmaceutical, and cell and gene therapy development and manufacture).

At GlaxoSmithKline he served as Senior Vice President, Chief Immunology Officer, and Global Development Leader. He oversaw the creation of a portfolio of new medicines (five have been approved).

He led Candel Therapeutics to an Initial Public Offering (IPO) on the Nasdaq (CADL), and a successful pivotal phase 3 clinical trial in localized prostate cancer, awarded with the 2025 SCRIP Award for Best Oncology R&D Advance. He is currently on the Board of Sitryx Therapeutics (Co-founder), Levicept, and Citryll (Chair) as well as on the Board of Trustees of the Kennedy Trust for Rheumatology Research.